Three-weekly Docetaxel with Prednisone is Feasible for Japanese Patients with Hormone-refractory Prostate Cancer: A Retrospective Comparative Study with Weekly Docetaxel Alone
| Autor: | Naoto Miyanaga, Toru Shimazui, Akira Joraku, Koji Kawai, Shiro Hinotsu, Takehiro Oikawa, Takahiro Kojima, Hideyuki Akaza, Noritoshi Sekido |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal Antineoplastic Agents Docetaxel urologic and male genital diseases Drug Administration Schedule Prostate cancer Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Radiology Nuclear Medicine and imaging Survival rate Retrospective Studies Tumor size business.industry Prostatic Neoplasms General Medicine Prostate-Specific Antigen medicine.disease Hormone refractory prostate cancer Regimen Toxicity Taxoids business medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 37:603-608 |
| ISSN: | 1465-3621 0368-2811 |
| Popis: | Background: We previously reported that weekly treatment with docetaxel alone is useful for and well tolerated by patients with hormone-refractory prostate cancer (HRPC). Here, we compare it with the regimen of docetaxel once every 3 weeks (q3w) plus daily prednisone (PSL) based on a TAX 327 trial in order to clarify the efficacy and toxicity of docetaxel regimens in Japan. Methods: Thirty-two patients with HRPC were treated with docetaxel weekly (regimen 1) or docetaxel q3w plus PSL daily (regimen 2) at Tsukuba University Hospital and the changes in serum prostate-specific antigen (PSA), tumor size and survival were evaluated. The dose of docetaxel in regimen 1 was based on our previous report and that of regimen 2 was modified from a TAX 327 trial. Results: A .50% decrease in PSA was observed in 53% of the patients with a median time to progression of 3.5 months and 69% with 8.5 months with regimens 1 and 2, respectively. Patients who received regimen 2 had a significantly better survival rate than those who received regimen 1. Myelosuppression and neuropathy were statistically more frequent in regimen 2 than in regimen 1. Conclusion: A regimen of docetaxel q3w with PSL daily was associated with a high rate of PSA reduction and prolongation of patient survival. Although docetaxel has not been approved in Japan yet, this treatment is considered feasible for Japanese patients with HRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|